These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 22096931)

  • 21. [Future of antiviral therapy for chronic hepatitis C. Direct antiviral acting medications].
    Lange CM; Sarrazin C; Zeuzem S
    Pharm Unserer Zeit; 2011 Jan; 40(1):60-7. PubMed ID: 21194084
    [No Abstract]   [Full Text] [Related]  

  • 22. [New triple therapy in chronic hepatitis C. Increased patient chances].
    Stiefelhagen P
    MMW Fortschr Med; 2011 Sep; 153(39):20. PubMed ID: 21991830
    [No Abstract]   [Full Text] [Related]  

  • 23. [Treatment for chronic hepatitis C, more opportunity, more challenge].
    Wei L
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):481-3. PubMed ID: 19912676
    [No Abstract]   [Full Text] [Related]  

  • 24. Mutations in hepatitis C virus NS3 protease domain associated with resistance to specific protease inhibitors in antiviral therapy naïve patients.
    Peres-da-Silva A; de Almeida AJ; Lampe E
    Arch Virol; 2010 May; 155(5):807-11. PubMed ID: 20405151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current and future management of chronic hepatitis C infection.
    Cross TJ; Antoniades CG; Harrison PM
    Postgrad Med J; 2008 Apr; 84(990):172-6. PubMed ID: 18424572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A review of HCV protease inhibitors.
    Chen KX; Njoroge FG
    Curr Opin Investig Drugs; 2009 Aug; 10(8):821-37. PubMed ID: 19649927
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel approaches for therapy of chronic hepatitis C.
    Stauber RE; Stadlbauer V
    J Clin Virol; 2006 Jun; 36(2):87-94. PubMed ID: 16546442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Hepatitis C is curable. Even slightly elevated liver enzymes need further examination].
    Niederau C
    MMW Fortschr Med; 2008 Mar; 150(13):26. PubMed ID: 18522352
    [No Abstract]   [Full Text] [Related]  

  • 29. [Perspectives in hepatology in the next 2-3 years: what will be clinically relevant? Viral hepatitis].
    Friedrich-Rust M; Forestier N; Zeuzem S
    Dtsch Med Wochenschr; 2005 Dec; 130 Suppl 5():S229-30. PubMed ID: 16435720
    [No Abstract]   [Full Text] [Related]  

  • 30. Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells.
    Lin K; Kwong AD; Lin C
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4784-92. PubMed ID: 15561857
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis C: current and future therapies.
    Mishra P; Jensen DM
    Mt Sinai J Med; 2008 Aug; 75(4):405-14. PubMed ID: 18729159
    [No Abstract]   [Full Text] [Related]  

  • 32. Antiviral combination therapy for treatment of chronic hepatitis B, hepatitis C, and human immunodeficiency virus infection.
    Hofmann WP; Soriano V; Zeuzem S
    Handb Exp Pharmacol; 2009; (189):321-46. PubMed ID: 19048206
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An update on treatment of hepatitis C virus genotype 1 infection and viral load assessments.
    Cobb B; Vilchez RA
    Hepatology; 2012 Mar; 55(3):979-80; author reply 980-1. PubMed ID: 22161994
    [No Abstract]   [Full Text] [Related]  

  • 34. Phase 1 trial starts for HCV protease inhibitor.
    AIDS Patient Care STDS; 2009 Mar; 23(3):225. PubMed ID: 19866544
    [No Abstract]   [Full Text] [Related]  

  • 35. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects.
    Bartels DJ; Zhou Y; Zhang EZ; Marcial M; Byrn RA; Pfeiffer T; Tigges AM; Adiwijaya BS; Lin C; Kwong AD; Kieffer TL
    J Infect Dis; 2008 Sep; 198(6):800-7. PubMed ID: 18637752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimization of novel acyl pyrrolidine inhibitors of hepatitis C virus RNA-dependent RNA polymerase leading to a development candidate.
    Slater MJ; Amphlett EM; Andrews DM; Bravi G; Burton G; Cheasty AG; Corfield JA; Ellis MR; Fenwick RH; Fernandes S; Guidetti R; Haigh D; Hartley CD; Howes PD; Jackson DL; Jarvest RL; Lovegrove VL; Medhurst KJ; Parry NR; Price H; Shah P; Singh OM; Stocker R; Thommes P; Wilkinson C; Wonacott A
    J Med Chem; 2007 Mar; 50(5):897-900. PubMed ID: 17269759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Hepatitis C: therapeutic perspectives].
    Trépo C
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B297-302. PubMed ID: 12180304
    [No Abstract]   [Full Text] [Related]  

  • 38. Hepatitis C virus therapies.
    Smith RE
    Nat Rev Drug Discov; 2006 Sep; 5(9):715-6. PubMed ID: 17001802
    [No Abstract]   [Full Text] [Related]  

  • 39. A highly efficient, asymmetric synthesis of benzothiadiazine-substituted tetramic acids: potent inhibitors of hepatitis C virus RNA-dependent RNA polymerase.
    Fitch DM; Evans KA; Chai D; Duffy KJ
    Org Lett; 2005 Nov; 7(24):5521-4. PubMed ID: 16288546
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Simeprevir (Olysio) for chronic hepatitis C.
    Med Lett Drugs Ther; 2014 Jan; 56(1433):1-3. PubMed ID: 24419295
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.